JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fouts, J. R.
Right arrow Articles by Brodie, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fouts, J. R.
Right arrow Articles by Brodie, B. B.
Journal of Pharmacology And Experimental Therapeutics, Vol. 116, Issue 4, 480-485, 1956
Copyright © 1956 by American Society for Pharmacology and Experimental Therapeutics

ON THE MECHANISM OF DRUG POTENTIATION BY IPRONIAZID (2-ISOPROPYL-1-ISONICOTINYL HYDRAZINE)

J. R. Fouts 1 and Bernard B. Brodie 1

1 The Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Public Health Service, U. S. Department of Health, Education and Welfare, Bethesda, Maryland

Marsilid, a compound almost devoid of sedative action, prolongs the hypnotic activity of hexobarbital in mice by interference with the rate of its metabolic transformation.

Marsilid inhibits oxidative enzyme systems in liver microsomes which oxidize the side chain of hexobarbital, dealkylate aminopyrine, deaminate amphetamine, and hydroxylate acetanilide. The biotransformation of these drugs is also inhibited by beta-diethylaminoethyl diphenylpropylacetate (SKF 525-A) and 2,4-dichloro-6-phenylphenoxyethyl diethylamine (Lilly 18947).

The mechanism of inhibition of drug metabolisms by Marsilid is, like that of SKF 525-A and Lilly 18947, unknown. It is presumably not due to an interchange of Marsilid with the nicotinamide moiety of the pyridine nucleotides DPN or TPN. Despite their dissimilarity in structure, Marsilid, Lilly 18947, and SKF 525-A probably act by a similar mechanism.

Submitted on November 21, 1955




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
A. BERNSTEIN and F. SIMON
Chlorpromazine and Iproniazid Toxic Hepatitis in the Same Patient
Arch Intern Med, June 1, 1959; 103(6): 954 - 956.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1956 by the American Society for Pharmacology and Experimental Therapeutics.